Quantcast
Last updated on April 18, 2014 at 5:47 EDT

Latest ovarian cancer Stories

2013-10-27 23:04:03

Mike Keliher, one of the founders of affinity social network community "Go Blue Then and Now" joins Kicking For The Dream in its effort in to fight against ovarian cancer, according to Kicking For The Dream founder NFL kicker Billy Cundiff. Phoenix, AZ (PRWEB) October 27, 2013 Mike Keliher, one of the founders of affinity social network community "Go Blue Then and Now" has joined Kicking For The Dream effort to fight against ovarian cancer according to Kicking For The...

2013-10-24 08:36:30

Newly Insured to Receive Access to Preventive Genetics Services ST. PETERSBURG, Fla., Oct. 24, 2013 /PRNewswire/ -- The most important way to join the fight against breast cancer is to educate women about their individual risk, and the options for those at high risk. "The majority of women do not have a BRCA gene mutation, but other factors may place some at high risk for breast cancer," said Amber Trivedi, M.S., C.G.C., who leads genetics educational initiatives at InformedDNA....

2013-10-22 12:28:48

Virginia-based HDL, Inc. will acquire and operate Oncimmune's Kansas lab and become exclusive licensed U.S. provider of EarlyCDT- Lung, world's first autoantibody test for early detection of lung cancer RICHMOND, Va., Oct. 22, 2013 /PRNewswire/ -- Health Diagnostic Laboratory, Inc. has acquired substantially all of the assets of Oncimmune USA, LLC, the subsidiary of Oncimmune Ltd., a United Kingdom-based company that developed, patented and commercialized a simple physician-ordered...

2013-10-21 08:29:23

Extension of Progression-Free Survival Observed Compared to Last Prior Therapy SAN DIEGO, Oct. 21, 2013 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced results from a Phase I first-in-human, single-agent clinical study of its investigational mitochondrial inhibitor drug candidate, ME-344, in patients with refractory solid tumors. The results, presented yesterday at the AACR-NCI-EORTC...

2013-10-21 08:28:36

ROCKVILLE, Md., Oct. 21, 2013 /PRNewswire/ -- EntreMed, Inc. (NASDAQ:ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced today the presentation of preclinical data from a study to assess the role of p53 family tumor suppressors in mediating response to ENMD-2076 in triple-negative breast cancer (TNBC). The study was led by Dr. Jennifer R. Diamond of University of Colorado and the results were presented at the...

2013-10-20 23:02:31

Colleen's Dream Foundation supports ovarian cancer research led by Niki M. Zacharias Millward, Ph.D. Phoenix, AZ (PRWEB) October 20, 2013 In its ongoing effort to support ovarian cancer research, Colleen’s Dream Foundation has gifted $10,000 to The University of Texas MD Anderson Cancer Center for cutting edge ovarian cancer research according to Colleen’s Dream Foundation President Billy Cundiff. "MD Anderson is at the forefront of cancer research and attracts some of the...

2013-10-17 16:37:52

Researchers announced today in the journal Lancet Oncology that they are well on the way to discovering why women with the faulty genes BRCA 1 and BRCA 2, one of which was inherited by the actress Angelina Jolie, develop breast and ovarian cancer rather than other cancers. The study, carried out by researchers at the UCL Department of Women's Cancer, found that abnormal levels of female hormones in the bloodstream could be the answer. The findings have already led to more research into...

2013-10-16 16:25:36

MIAMI, Oct. 16, 2013 /PRNewswire-USNewswire/ -- In a study to be published today in Scientific Reports, researchers from the Florida International University Herbert Wertheim College of Medicine and the FIU College of Engineering and Computing describe what could be a breakthrough in the treatment of ovarian cancer: a novel way to deliver cancer-killing drugs using nanotechnology. In their lab experiments, Taxol, a chemotherapy drug used to treat ovarian cancer, was loaded unto a...

2013-10-15 08:33:34

Also Releases Results from National Harris Survey Revealing Widespread Confusion about BRCA Testing MADISON, N.J., Oct. 15, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced the availability of BRCAvantage(TM), a suite of four new lab-developed genetic tests (LDT) that identify mutations in BRCA1 and BRCA2 genes, which are associated with increased risk of inherited breast and ovarian cancers. Serving...

2013-10-15 08:29:13

Seventy-two Percent (72 percent) of Adult Women in the U.S. Have Never Heard of BRCA Testing, yet 58 Percent Would Want to Know if They Carried High-Risk Gene Mutations MADISON, N.J., Oct. 15, 2013 /PRNewswire/ -- According to the results of a recent Quest Diagnostics (NYSE: DGX) survey, seventy-two percent (72 percent) of American women age 18 and older have never heard of the BRCA test, a genetic test that can identify mutations in BRCA1 and BRCA2 genes associated with increased risk of...


Latest ovarian cancer Reference Libraries

Ovaries
2013-03-05 14:55:04

The ovaries are the two reproductive female organs where the eggs are produced. These are parallel to the testes in men. Formation and Orientation Each ovary is the size of an almond and is located on one side of the pelvis before the ureter and internal iliac artery but after the external iliac artery. They are attached to either side of the uterus. They are connected and release eggs to fallopian tubes, though not attached, monthly during the menstrual cycle. They also produce...

More Articles (1 articles) »